WEST Search History

DATE: Monday, November 24, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ			
L4	L3 and nucleoside	20	L4
L3	L2 and (tetrazol$2 with ammonium)	23	L3
L2	L1 and tetrazole	780	L2
DB=USPT; PLUR=YES; OP=ADJ			
L1	((435/91.1)!.CCLS. |(558/70)!.CCLS. |(536/23.1 |536/25.1 |536/25.34 |536/24.5)!.CCLS.)	10320	L1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 12:01:28 ON 24 NOV 2003)

FILE 'REGISTRY' ENTERED AT 12:01:36 ON 24 NOV 2003

L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 0 S L1 SSS FULL

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 12:03:23 ON 24 NOV 2003

L4 1660 S INTERNUCLEOSIDE
L5 1660 S L4
L6 576 S L5 AND TETRAZOLE
L7 688 S L5 AND TETRAZOL?
L8 620 S L7 AND (AMMONIUM OR PYRIDINIUM)
L9 592 S L8 AND SUPPORT
L10 525 S L9 AND PYRIDINE
L11 6 S L10 AND METHYLPYRIDINE
L12 3 S L10 AND AMMONIUM TETRAZOLIDE

L12 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER:	2000:88317 USPATFULL			
TITLE:	Dinucleotide and oligonucleotide analogues			
INVENTOR(S):	Baxter, Anthony David, Abingdon, United Kingdom Baylis, Eric Keith, Stockport, United Kingdom Collingwood, Stephen Paul, Crawley, United Kingdom Fairhurst, Robin Alec, Ashington, United Kingdom Taylor, Roger John, Southwater, United Kingdom			
PATENT ASSIGNEE(S):	Novartis AG, Basel, Switzerland (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6087490		20000711	
	WO 9735869		19971002	
APPLICATION INFO.:	US 1998-155198		19981008	(9)
	WO 1997-GB651		19971103	
			19981008	PCT 371 date
			19981008	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	GB 1996-6158		19960323	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Riley, Jezia			
LEGAL REPRESENTATIVE:	Borovian, Joseph J.			
NUMBER OF CLAIMS:	18			
EXEMPLARY CLAIM:	1			
LINE COUNT:	2923			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound which is a dinucleotide analogue of formula ##STR1## or a salt thereof, where B.sup.1 and B.sup.2 are each independently a monovalent nucleoside base radical,

R.sup.1 is hydrogen or Y.sup.1,

R.sup.2 and R.sup.3 are each independently hydrogen, halogen, hydroxy or --OY.sup.2,

R.sup.4 is hydrogen, halogen, hydroxy, --OY.sup.3 or R.sup.7,

R.sup.5 is hydrogen, halogen or R.sup.8,

R.sup.6 is hydrogen, Y.sup.4 or a phosphoramidyl group,

Z is a group of formula II, III or IV ##STR2## where R.sup.9 is hydrogen, halogen, hydroxy, --OY.sup.5 or R.sup.13, R.sup.10 is hydrogen, halogen or R.sup.14, R.sup.11 is hydroxy, R.sup.15 or --OR.sup.15 where R.sup.15 is a C.sub.1 to C.sub.10 aliphatic group, a C.sub.3 to C.sub.8 cycloaliphatic group, a C.sub.6 to C.sub.10 aromatic group or a C.sub.7 to C.sub.13 araliphatic group, and R.sup.12 is hydrogen, R.sup.12.sub.a or --OCOR.sup.12.sub.a where R.sup.12.sub.a is a C.sub.1 to C.sub.10 aliphatic group, a C.sub.3 to C.sub.8 cycloaliphatic group, a C.sub.6 to C.sub.10 aromatic group or a C.sub.7 to C.sub.13 araliphatic group, Y.sup.1, Y.sup.2, Y.sup.3, Y.sup.4 and Y.sup.5 are each indpendently a hydroxy-protecting group, and R.sup.7, R.sup.8, R.sup.13 and R.sup.14 are each independently a C.sub.1 to C.sub.10 aliphatic group, a C.sub.3 to C.sub.8 cycloaliphatic group, a C.sub.6 to C.sub.10 aromatic group or a C.sub.7 to C.sub.13 araliphatic group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2000:64673 USPATFULL
TITLE: Modified oligonucleotides
INVENTOR(S): De Mesmaeker, Alain, Kanerkinden, Switzerland
Waldner, Adrian, Allschwil, Switzerland
Lebreton, Jacques, Marseilles, France
Bevierre, Marc-Olivier, Fontainebleau, France
Lesueur, Catherine, Chambray-les-Tours, France
PATENT ASSIGNEE(S): Novartis Corporation, Summit, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6066447		20000523	
	WO 9520597		19950803	
APPLICATION INFO.:	US 1996-687456		19961112	(8)
	WO 1995-EP156		19950117	
			19961112	PCT 371 date
			19961112	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-1446	19940126
	GB 1994-12526	19940622

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Harschel, Ardin H.
LEGAL REPRESENTATIVE: Ferraro, Gregory D.
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 2207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Oligonucleotides of the formula: 5'(U).sub.n -3' in which U is an identical or different radical of a natural or a synthetic nucleoside and n is a number from 2 to 200 comprising at least one structural unit of two consecutive nucleosides wherein one of the nucleotides is substituted in the 2'-position or wherein the nucleotides are substituted differently in their 2'-position and wherein the backbone is modified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2000:47356 USPATFULL
TITLE: Process for the synthesis of oligomeric compounds
INVENTOR(S): Ravikumar, Vasulinga T., Carlsbad, CA, United States
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6051699		20000418	
	WO 9719092		19970529	
APPLICATION INFO.:	US 1998-68275		19980506	(9)
	WO 1996-US18618		19961115	
			19980506	PCT 371 date
			19980506	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-560540, filed on 17 Nov 1995, now patented, Pat. No. US 5705621
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wilson, James O.
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP
NUMBER OF CLAIMS: 62

EXEMPLARY CLAIM: 1
LINE COUNT: 2479
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Synthetic processes are provided wherein oligomeric compounds are prepared having phosphodiester, phosphorothioate, and phosphorodithioate covalent linkages. Also provided are synthetic intermediates useful in the processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>